Patents by Inventor Ulrich G. Steidl

Ulrich G. Steidl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-BASED METHOD TO IDENTIFY, PURIFY, AND MANIPULATE CELL TYPES AND PROCESSES
    Publication number: 20220227886
    Abstract: This disclosure relates to compositions and methods of identifying, isolating, and modulating cells and tissues based on their cellular glycosaminoglycan pattern. In some aspects, provided are anti-GAG motif antibodies or antigen-binding fragments thereof and their use for determining a glycosaminoglycan (GAG) glycotype for a cell. Also provided are methods of isolating cells, identifying cells, detecting a disease or disorder, and/or treating a disease or disorder based on a cellular glycotype.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 21, 2022
    Applicant: Albert Einstein College of Medicine
    Inventors: Hannes E. Buelow, Ulrich G. Steidl, Steven C. Almo, Robert A. Townley, Richard Pisczcaztowski, Ron Seidel, III
  • BAX activators and uses thereof in cancer therapy
    Patent number: 11382898
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20200093802
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Application
    Filed: May 24, 2018
    Publication date: March 26, 2020
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • Treatment of acute myeloid leukemia and myelodysplastic syndromes
    Patent number: 9873918
    Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: January 23, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Ulrich G. Steidl, Laura Barreyro De Pujato, Britta Will, Amit Verma
  • EPIGENETIC STEM CELL COMMITMENT-ASSOCIATED SIGNATURE
    Publication number: 20160340737
    Abstract: Methods for determining the prognosis of a subject having acute myeloid leukemia (AML) as well as methods of treating AML subjects depending on prognosis.
    Type: Application
    Filed: December 29, 2014
    Publication date: November 24, 2016
    Applicant: Albert Einstein College of Medicine, Inc.
    Inventors: Ulrich G. Steidl, Amit Verma, Boris Bartholdy, Maximilian Christopeit
  • PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
    Publication number: 20150359815
    Abstract: Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1).
    Type: Application
    Filed: September 4, 2015
    Publication date: December 17, 2015
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: ULRICH G. STEIDL, ASHLEY M. PANDOLFI, ROBERT F. STANLEY
  • THERAPEUTIC AND DIAGNOSTIC TARGET GENE IN ACUTE MYELOID LEUKEMIA
    Publication number: 20150299336
    Abstract: Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided.
    Type: Application
    Filed: March 26, 2015
    Publication date: October 22, 2015
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Ulrich G. Steidl
  • TARGETS FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
    Publication number: 20150147271
    Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.
    Type: Application
    Filed: August 9, 2012
    Publication date: May 28, 2015
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ulrich G. Steidl, Laura Barreyro De Pujato, Britta Will
  • THERAPEUTIC AND DIAGNOSTIC TARGET GENE IN ACUTE MYELOID LEUKEMIA
    Publication number: 20140187604
    Abstract: Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided.
    Type: Application
    Filed: May 3, 2012
    Publication date: July 3, 2014
    Applicants: Dana-Farber Cancer Institute, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ulrich G. Steidl, Constantine S. Mitsiades